References

Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility

10.1111/bjd.18921 · 2020 · External reference

Inherited epidermolysis bullosa: updated recommendations on diagnosis and classification

10.1016/j.jaad.2014.01.903 · 2014 · External reference

Extracutaneous manifestations and complications of inherited epidermolysis bullosa: part I. Epithelial associated tissues

10.1016/j.jaad.2009.03.052 · 2009 · External reference

Treatment of epidermolysis bullosa and future directions: a review

10.1007/s13555-024-01227-8 · 2024 · External reference

Trial of beremagene geperpavec (B-VEC) for dystrophic epidermolysis bullosa

10.1056/nejmoa2206663 · 2022 · External reference

Efficacy and safety of oleogel-S10 (birch triterpenes) for epidermolysis bullosa: results from the phase III randomised double-blind phase of the EASE study

10.1093/bjd/ljac001 · 2023 · External reference

Prademagene zamikeracel for recessive dystrophic epidermolysis bullosa wounds (VIITAL): a two-centre, randomised, open-label, intrapatient-controlled phase 3 trial

10.1016/s0140-6736(25)00778-0 · 2025 · External reference

Clinical trials in rare disease: challenges and opportunities

10.1177/0883073813495959 · 2013 · External reference

Patient involvement in clinical research: why, when, and how

10.2147/ppa.s104259 · 2016 · External reference

Factors that impact on recruitment to randomised trials in health care: a qualitative evidence synthesis

10.1002/14651858.mr000045 · 2017 · External reference

Barriers to participation in clinical trials of cancer: a meta-analysis and systematic review of patient-reported factors

10.1016/s1470-2045(06)70576-9 · 2006 · External reference

Profiling trial burden and patients’ attitudes to improve clinical research in epidermolysis bullosa

10.1186/s13023-020-01443-3 · 2020 · External reference

Mitochondrial disease patient motivations and barriers to participate in clinical trials

10.1371/journal.pone.0197513 · 2018 · External reference

Clinical trial awareness, perceptions, and participation among cancer patients in Saudi Arabia

10.3390/healthcare13091044 · 2025 · External reference

Combined results of two cross-sectional surveys on the participation in clinical trials and the e-consent procedure in the landscape of haematology

10.3390/clinpract13060133 · 2023 · External reference

Incentives and payments in pragmatic clinical trials: scientific, ethical, and policy considerations

10.1177/17407745211048178 · 2021 · External reference

Hope for a cure and altruism are the main motives behind participation in phase 3 clinical trials

10.1111/ecc.12184 · 2015 · External reference

Genetic implications and management of epidermolysis bullosa in the Saudi Arabian population

10.7759/cureus.66678 · 2024 · External reference

A systematic literature review of the disease burden in patients with recessive dystrophic epidermolysis bullosa

10.1186/s13023-021-01811-7 · 2021 · External reference

The impact of epidermolysis bullosa on the family and healthcare practitioners: a scoping review

10.1111/ijd.16197 · 2023 · External reference

The patient’s view on rare disease trial design: a qualitative study

10.1186/s13023-019-1002-z · 2019 · External reference

What role can decentralised trial designs play to improve rare disease studies?

10.1186/s13023-022-02388-5 · 2022 · External reference